🇺🇸 ENFORTUMAB VEDOTIN in United States

1,472 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neuropathy Peripheral — 231 reports (15.69%)
  2. Rash — 223 reports (15.15%)
  3. Malignant Neoplasm Progression — 215 reports (14.61%)
  4. Decreased Appetite — 143 reports (9.71%)
  5. Diarrhoea — 132 reports (8.97%)
  6. Pruritus — 113 reports (7.68%)
  7. Inappropriate Schedule Of Product Administration — 110 reports (7.47%)
  8. Death — 104 reports (7.07%)
  9. Alopecia — 102 reports (6.93%)
  10. Fatigue — 99 reports (6.73%)

Source database →

ENFORTUMAB VEDOTIN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ENFORTUMAB VEDOTIN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ENFORTUMAB VEDOTIN in United States?

Marketing authorisation holder not available in our data.